Department of Dermatology, University of Ottawa, Ottawa.
Clin Infect Dis. 2011 Mar 1;52(5):e133-5. doi: 10.1093/cid/ciq213.
Erythema nodosum leprosum (ENL), or type II reaction, is a common complication of lepromatous leprosy that can cause significant patient debility. First-line therapy includes prednisone and thalidomide, with clofazimine reserved for patients who do not respond to first-line treatment. We present the case of a 33-year-old woman with ENL that failed to respond adequately to conventional therapy over a 6-year period. Because of the severe nature of her disease and the adverse effects of therapy that she experienced, a trial of etanercept was undertaken, which led to full resolution of her ENL. The rationale behind our choice of therapy and its future implications are discussed.
红斑结节性麻风反应（ENL），又称 II 型反应，是麻风病的一种常见并发症，可导致患者明显虚弱。一线治疗包括泼尼松和沙利度胺，氯法齐明则留作一线治疗无效的患者使用。我们报告了一例 33 岁女性患者，她在 6 年期间的 ENL 经常规治疗未能充分缓解。由于疾病的严重程度以及她所经历的治疗不良反应，我们尝试使用依那西普治疗，结果她的 ENL 完全缓解。我们选择该治疗方案的依据及其未来意义进行了讨论。
